{"generic":"Macitentan","drugs":["Macitentan","Opsumit"],"mono":{"0":{"id":"jy7ss0","title":"Generic Names","mono":"Macitentan"},"1":{"id":"jy7ss1","title":"Dosing and Indications","sub":{"0":{"id":"jy7ss1b4","title":"Adult Dosing","mono":"<ul><li>obtain pregnancy test in females of reproductive potential to rule out pregnancy prior to initiation of therapy; obtain monthly pregnancy test thereafter; all females, regardless of reproductive potential, must obtain macitentan through the Opsumit(R) REMS Program at 1-866-228-3546<\/li><li><b>Pulmonary hypertension:<\/b> 10 mg ORALLY once a day<\/li><\/ul>"},"1":{"id":"jy7ss1b5","title":"Pediatric Dosing","mono":"safety and efficacy not established in pediatric patients "},"3":{"id":"jy7ss1b7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Pulmonary hypertension<br\/>"}}},"2":{"id":"jy7ss2","title":"Black Box Warning","mono":"<b>Oral (Tablet)<\/b><br\/>Do not administer macitentan to a pregnant female because it may cause fetal harm. Exclude pregnancy before treatment initiation, monthly during treatment, and one month after treatment discontinuation in females of reproductive potential. Use acceptable contraception to prevent pregnancy during treatment and for one month after stopping treatment. Macitentan is only available for female patients through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS).<br\/>"},"3":{"id":"jy7ss3","title":"Contraindications\/Warnings","sub":[{"id":"jy7ss3b9","title":"Contraindications","mono":"Pregnancy; may cause fetal harm <br\/>"},{"id":"jy7ss3b10","title":"Precautions","mono":"<ul><li>Black Box Warning:<\/li><li>-- Pregnant female; may cause fetal harm; use contraindicated<\/li><li>-- Women of childbearing potential require adequate contraception during treatment and for one month after discontinuation; exclude pregnancy prior to use, monthly during treatment, and one month after discontinuation<\/li><li>Hematologic:<\/li><li>-- Decreases in hemoglobin concentration and hematocrit have been reported; monitoring recommended<\/li><li>-- Use not recommended in patients with severe anemia<\/li><li>Hepatic:<\/li><li>-- Hepatotoxicity, elevated aminotransferases, and liver failure have occurred with other endothelin receptor antagonists; monitoring recommended and discontinuation may be necessary<\/li><li>Reproductive:<\/li><li>-- Adverse effects on spermatogenesis have occurred with other endothelin receptor antagonists<\/li><li>Respiratory:<\/li><li>-- Pulmonary edema with pulmonary venoocclusive disease may occur; discontinue if confirmed<\/li><li>Concomitant Use:<\/li><li>-- Avoid strong CYP3A4 inducers, such as rifampin<\/li><li>-- Avoid strong CYP3A4 inhibitors, such as ketoconazole or ritonavir<\/li><\/ul>"},{"id":"jy7ss3b11","title":"Pregnancy Category","mono":"X (FDA)<br\/>"},{"id":"jy7ss3b12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"jy7ss4","title":"Drug Interactions","sub":{"1":{"id":"jy7ss4b14","title":"Major","mono":"<ul><li>Atazanavir (theoretical)<\/li><li>Boceprevir (theoretical)<\/li><li>Carbamazepine (theoretical)<\/li><li>Clarithromycin (theoretical)<\/li><li>Cobicistat (theoretical)<\/li><li>Conivaptan (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Enzalutamide (theoretical)<\/li><li>Fluconazole (theoretical)<\/li><li>Fosphenytoin (theoretical)<\/li><li>Idelalisib (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Itraconazole (theoretical)<\/li><li>Ketoconazole (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Mitotane (theoretical)<\/li><li>Nefazodone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Phenobarbital (theoretical)<\/li><li>Phenytoin (theoretical)<\/li><li>Posaconazole (theoretical)<\/li><li>Primidone (theoretical)<\/li><li>Rifabutin (theoretical)<\/li><li>Rifampin (theoretical)<\/li><li>Rifapentine (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Siltuximab (theoretical)<\/li><li>St John's Wort (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Telithromycin (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Voriconazole (theoretical)<\/li><\/ul>"}}},"5":{"id":"jy7ss5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Hematologic:<\/b>Anemia (13%)<\/li><li><b>Immunologic:<\/b>Influenza (6%)<\/li><li><b>Neurologic:<\/b>Headache (14%)<\/li><li><b>Renal:<\/b>Urinary tract infectious disease (9%)<\/li><li><b>Respiratory:<\/b>Bronchitis (12%), Nasopharyngitis, Pharyngitis<\/li><\/ul><b>Serious<\/b><br\/><b>Hepatic:<\/b>Increased liver aminotransferase level (2.1% to 3.4%)<br\/>"},"6":{"id":"jy7ss6","title":"Drug Name Info","sub":{"0":{"id":"jy7ss6b17","title":"US Trade Names","mono":"Opsumit<br\/>"},"2":{"id":"jy7ss6b19","title":"Class","mono":"<ul><li>Antihypertensive<\/li><li>Endothelin Receptor Antagonist<\/li><\/ul>"},"3":{"id":"jy7ss6b20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"jy7ss6b21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"jy7ss7","title":"Mechanism Of Action","mono":"Macitentan is an endothelin (ET) receptor antagonist with a high affinity for and long occupancy period of ET receptors in pulmonary arterial smooth muscle cells.<br\/>"},"8":{"id":"jy7ss8","title":"Pharmacokinetics","sub":[{"id":"jy7ss8b23","title":"Absorption","mono":"<ul><li>Tmax, Oral: 8  to 9 hours<\/li><li>Effect of food: no effect on exposure<\/li><\/ul>"},{"id":"jy7ss8b24","title":"Distribution","mono":"<ul><li>Protein binding, albumin and alpha-1-glycoprotein: greater than 99%<\/li><li>Vd: 50 L<\/li><\/ul>"},{"id":"jy7ss8b25","title":"Metabolism","mono":"<ul><li>Liver: extensive<\/li><li>ACT-132577: active<\/li><li>Substrate of CYP3A4 and CYP2C19<\/li><\/ul>"},{"id":"jy7ss8b26","title":"Excretion","mono":"<ul><li>Renal: 50%<\/li><li>Fecal: 24%<\/li><\/ul>"},{"id":"jy7ss8b27","title":"Elimination Half Life","mono":"<ul><li>Macitentan: 14.1  to 16 hours<\/li><li>Active metabolite: 46.7  to 48 hours<\/li><\/ul>"}]},"9":{"id":"jy7ss9","title":"Administration","mono":"<b>Oral<\/b><br\/>do not split, crush, or chew <br\/>"},"10":{"id":"jy7ss10","title":"Monitoring","mono":"<ul><li>improvement in exercise capacity, WHO functional class, and decrease in the rate of clinical worsening are indicative of efficacy<\/li><li>pregnancy tests, in all women of reproductive potential; prior to treatment, monthly during treatment, and for 1 month after discontinuation<\/li><li>liver enzymes; at baseline and as clinically indicated<\/li><li>hemoglobin; at baseline and as clinically indicated<\/li><\/ul>"},"11":{"id":"jy7ss11","title":"How Supplied","mono":"<b>Opsumit<\/b><br\/>Oral Tablet: 10 MG<br\/>"},"13":{"id":"jy7ss13","title":"Clinical Teaching","mono":"<ul><li>Counsel patients that drug may cause fetal harm. Advise female patients of reproductive potential that a negative pregnancy test is required prior to initiating therapy. Thereafter, pregnancy testing is required monthly during therapy, and for one month after treatment. Instruct all patients to use an adequate form of contraception during therapy. If pregnancy occurs during treatment, apprise patient of potential harm to fetus.<\/li><li>Side effects may include headache, bronchitis, influenza, or urinary tract infection.<\/li><li>Instruct prepubertal female patients to report changes in reproductive status.<\/li><li>Counsel patients to report symptoms of hepatotoxicity (eg, jaundice, darkened urine, fatigue, nausea, vomiting).<\/li><li>Tell patient to swallow tablets whole. Do not chew, crush, or split.<\/li><li>Advise patient there are multiple significant drug-drug interactions for this drug. Consult healthcare professional prior to new drug use (including over-the counter, nutritional supplements, vitamins, and herbal drugs).<\/li><\/ul>"}}}